U.S. Interactive Media and Services Stock News

Why Chart Industries’ latest earnings matter for shareholders Chart Industries (GTLS) just released fourth quarter and full year 2025 results, with both net income and sales below the prior year and revenue and earnings missing Wall Street forecasts. See our latest analysis for Chart Industries. At a share price of $207.30, Chart Industries has seen relatively steady recent trading, with a 90 day share price return of 1.60% and a 1 year total shareholder return of 8.79%. This suggests that...

Analysts have recently raised their earnings estimates for InnovAge Holding (INNV) for both the current quarter and full year. This shift in expectations appears to be a key catalyst for the stock. See our latest analysis for InnovAge Holding. The recent upward revisions to earnings expectations come after a sharp run in the shares, with a 30 day share price return of 61.44% and a 1 year total shareholder return of 175.69%. This suggests momentum has recently picked up despite a weaker 5 year...

If you are wondering whether Spectrum Brands Holdings is still attractively priced or already reflecting its potential, you are in the right place for a clear, valuation focused look at the stock. The share price recently closed at US$78.38, with returns of 23.0% over 30 days and 30.5% year to date, while the 1 year return sits at 4.4% and the 3 and 5 year returns are 28.8% and 8.8% respectively. This naturally raises questions about how much value is already priced in. Recent news around...

Avista (AVA) just posted its full year 2025 results, reporting higher earnings, a 24th consecutive annual dividend increase to US$1.97 per share, and updated guidance along with regulatory and project developments that drew investor attention. See our latest analysis for Avista. At a share price of US$40.62, Avista has seen a 1 day share price return of 2.14% and a year to date share price return of 4.91%. Its 1 year total shareholder return of 6.78% and 5 year total shareholder return of...

Commercial Metals (CMC) is drawing fresh attention as it heads into its fiscal Q2 2026 earnings release and webcasted conference call, following two recent concrete products acquisitions. See our latest analysis for Commercial Metals. Recent trading has cooled after a strong run, with a 1 day share price return of 2.15% decline and a 30 day share price return of 5.98% decline. However, the 1 year total shareholder return of 53.28% and 5 year total shareholder return of 173.11% point to...

Claritev Corporation recently reported past fourth-quarter 2025 sales of US$246.55 million and a net loss of US$80.57 million, alongside full-year 2025 sales of US$965.41 million and a net loss of US$284.28 million, and announced a new share repurchase program of up to US$75 million running through 2030. While the company remains loss-making, the year-on-year reduction in losses and the commitment to buying back shares suggest management is focused on improving financial discipline and...

Perdoceo Education (PRDO) drew fresh attention after reporting fourth quarter and full year 2025 earnings, issuing new 2026 guidance, and affirming its quarterly dividend, giving investors several data points to reassess the stock. See our latest analysis for Perdoceo Education. The recent earnings, 2026 guidance and dividend affirmation come after a period of steady share price strength, with a 90 day share price return of 19.83% and a 1 year total shareholder return of 32.10% supporting a...

Glaukos (GKOS) is back in focus after its fourth quarter 2025 report paired strong sales figures with a sizeable impairment charge, followed shortly by fresh 2026 sales guidance and a new ESOP related shelf registration. See our latest analysis for Glaukos. The recent impairment charge and ESOP related shelf registration come against a backdrop of steady share price gains, with a 90 day share price return of 13.28% and a very large 3 year total shareholder return of 139.03%. This suggests...

Xeris Biopharma recently filed a Hatch-Waxman patent infringement lawsuit in the US District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics, seeking to block generic versions of its Cushing’s syndrome therapy Recorlev until its patents expire in March 2040. This legal move highlights how central Recorlev’s intellectual property protection is to Xeris’s long-term product exclusivity and potential revenue longevity in its endocrine...

Why Sealed Air is on investors’ radar today Sealed Air (SEE) is back in focus after recent trading left the shares around $41.88, prompting investors to reassess how its packaging business and current valuation line up with their expectations. See our latest analysis for Sealed Air. While the 1-day and 7-day share price returns are slightly negative, Sealed Air’s 1-year total shareholder return of 25.46% contrasts with weaker 3-year and modest 5-year total shareholder returns, which suggests...

EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer, giving him responsibility for commercial strategy and launch preparation for DURAVYU, its Phase 3 retinal disease candidate. The hire brings in a leader who helped shape the commercial playbooks behind Lucentis, Xiidra, Beovu and Tyrvaya, directly relevant to DURAVYU’s target markets. We’ll now examine how adding a veteran ophthalmology launch executive to oversee DURAVYU’s commercialization may influence...

Omnicell has recently accelerated its shift from hardware-focused sales toward software and services, including acquiring ANiGENT in October 2025 to broaden its drug diversion detection capabilities and recurring revenue base. This pivot toward subscription-like revenue streams is prompting investors to reassess Omnicell less as a traditional equipment maker and more as a healthcare IT provider, with different expectations for growth, risk and valuation. Next, we’ll examine how Omnicell’s...

In Q4 2025, Harbor Capital Advisors' Mid Cap Value Fund disclosed that it had initiated a new position in EnerSys, citing improving operating margins, sales growth, strong cash flow, ongoing share buybacks, and regular dividend payments as key reasons for the investment. The fund also ranked EnerSys in the top 5% of its evaluation universe, highlighting how the company’s combination of operating momentum and capital returns screens well against a broad mid-cap peer group. Next, we’ll examine...

Valley National Bancorp (VLY) shares dropped 6.2% as hotter inflation data and growing credit risk worries pressured regional lenders, even though the bank confirmed regular dividends and a new share repurchase authorization. See our latest analysis for Valley National Bancorp. Despite the latest 5.7% one day share price decline to US$12.61, Valley National Bancorp’s 90 day share price return of 9.8% and 1 year total shareholder return of 34.0% suggest momentum has generally been positive...

Arcosa (ACA) is back on investors’ radar after a recent share pullback over the past week and month, drawing attention to how its infrastructure focused business and current valuation metrics stack up today. See our latest analysis for Arcosa. The sharp 1 day share price decline of 15.7% and 7 day share price return of 14.9% sit against a 1 year total shareholder return of 28.42% and 5 year total shareholder return of 84.39%. This suggests recent momentum has cooled after a strong multi year...

In February 2026, Ladder Capital Corp. announced it had secured US$675 million in new unsecured capital commitments, expanding its unsecured revolving credit facility to US$1.25 billion and adding a US$275 million unsecured delayed draw term loan priced at 140 basis points over SOFR. This package of same-day liquidity at 125 basis points over SOFR and long-dated funding to 2030 materially strengthens Ladder’s funding flexibility and duration profile. Next, we’ll examine how this expanded...

Regency Centers completed a public offering of $450 million in senior unsecured notes due 2033. The issuance is intended to support balance sheet optimization and ongoing development activities. The company trades on the NasdaqGS under the ticker NasdaqGS:REG, with a current share price of $79.0. For investors watching NasdaqGS:REG, this $450 million notes offering is a fresh data point on how Regency Centers is managing its capital structure. The stock is at $79.0, with returns of 2.8%...

LPL Financial Holdings (LPLA) has drawn attention after a period of weaker share performance, with returns over the past month, past 3 months, and year all in negative territory, even though multi year total returns remain positive. See our latest analysis for LPL Financial Holdings. The recent 1 month share price return of a 17.59% decline and year to date share price return of a 16.94% decline point to fading near term momentum, even though the 5 year total shareholder return of 129.88%...

Owens Corning (NYSE:OC) reported a net loss for the fourth quarter, reversing net income from the same period a year earlier. The company also posted a full year net loss, a material deterioration compared with the prior year's profitability. Recent results came in below earnings expectations, highlighting weaker than anticipated financial performance. For investors watching NYSE:OC, this shift to losses comes with the stock recently closing at $122.07. Shares are down 8.0% over the past...

If you are wondering whether Boise Cascade's share price still reflects its real worth, looking at how the market has treated the stock over different time frames is a useful starting point. The stock last closed at US$82.74, with returns of 0.7% over 7 days, 3.0% over 30 days, 11.6% year to date, but a 19.3% decline over 1 year and longer term returns of 36.4% over 3 years and 107.2% over 5 years. Recent headlines around Boise Cascade have focused on its position as a major supplier of...

FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 ATTR amyloidosis trial, allowing global enrollment to resume with updated safety protocols. Intellia completes phase 3 enrollment ahead of schedule in the HAELO trial for lonvo-z, a one time gene editing therapy for hereditary angioedema. These steps advance Intellia Therapeutics' late stage pipeline and move its gene editing candidates closer to potential approval and commercialization. For investors watching Intellia...

If you are trying to work out whether Lineage at around US$40.52 is a bargain or just fairly priced, you are in the right place. The stock has recently posted returns of 5.8% over 7 days, 12.6% over 30 days and 14.4% year to date, although the 1 year return sits at a 29.3% decline. Recent attention on Lineage has focused on its position in the US real estate space and how investors are reassessing companies in the sector, which helps frame these recent price moves. Coverage has regularly...

Thermon Group Holdings (NYSE:THR) has entered into a definitive agreement to be acquired by CECO Environmental Corp. in a cash and stock deal. The transaction proposes different forms of consideration for existing Thermon shareholders, subject to customary approvals. Law firms have launched investigations into whether the terms of the acquisition are fair to Thermon shareholders. Thermon shares most recently closed at $50.78, with the stock showing returns of 34.9% year to date and 72.1%...

Wondering if Warby Parker at around US$25.01 is priced for its brand story or for its actual fundamentals? This article breaks down what the current share price may be implying about value. The stock has had a mixed run, with a 5.5% return over the past week, a 2.0% decline over the last 30 days, a 10.6% return year to date and a 1.1% return over the past year, while the 3 year return sits at 100.4%. Recent headlines around Warby Parker have focused on its position in the US eyewear retail...